Opmbiosciences provides specialized cell culture media and end‑to‑end CDMO services for biopharma and biotech companies. Their media are optimized for consistency, scalability, and regulatory compliance across mammalian, microbial, and stem‑cell platforms, while their GMP‑certified facilities handle process development, scale‑up, and commercial manufacturing under a single‑source project management model.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharmaceutical companies often face challenges sourcing high-quality cell culture media and managing complex contract development and manufacturing processes, leading to delays and variability in product development.
Solution
Opmbiosciences offers a portfolio of specialized cell culture media combined with end‑to‑end CDMO (Contract Development and Manufacturing Organization) services. Their media formulations are optimized for consistency, scalability, and regulatory compliance, supporting a range of cell lines used in biologics production. The CDMO platform handles process development, scale‑up, and GMP manufacturing, providing a single point of contact that streamlines project timelines and reduces the need for multiple vendors. Integrated quality control and data management ensure traceability and reproducibility across all stages of development.
Target Audience
Primary customers are biopharma and biotech companies seeking reliable cell culture media and comprehensive CDMO services for biologics and cell‑based therapies.
Features
- Customizable cell culture media formulations for mammalian, microbial, and stem cell platforms
- GMP‑certified manufacturing facilities with capabilities from pilot to commercial scale
- Full process development services including cell line selection, media optimization, and bioreactor design
- Integrated analytical and quality control testing to meet regulatory standards
- Single‑source project management platform that coordinates development, manufacturing, and logistics